CLOs on the Move


 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Similar Companies

SkinMedica

SkinMedica, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Steakholder Foods

Meat. It’s an ancient and universal tradition. A story of human evolution and progress, family and culture. A story of our relationship with animals. With the

Aastrom

We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.

FirstString Research Inc

FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.